OR WAIT null SECS
July 21, 2020
Catalent has unveiled plans to invest in a European center of excellence for clinical biologics formulation development and drug product fill/finish services at its facility in Limoges, France.
July 08, 2020
The acquisition will give the CDMO additional clinical filling options in Europe, which is expected to come online in 2021.
July 06, 2020
Lonza is making additional investments in its global particle engineering network for expanded capacity and specialized capabilities.
July 02, 2020
Demand for custom drug delivery solutions is increasing and bringing forth an exciting period of valuable, innovative development opportunities.
The COVID-19 pandemic has created a rise in demand for R&D and a shift in focus for some contract organizations.
May 04, 2020
FDA approved hydroxychloroquine sulfate for emergency use as a treatment for some hospitalized patients with COVID-19.
May 02, 2020
Will moving at “warp speed” to develop a vaccine impact efficacy or safety?
April 30, 2020
Catalent and Johnson & Johnson announce joint investment and tech transfer to prepare for rapid scale-up and segregated cGMP commercial manufacturing capacity.
April 02, 2020
The new molecules entering the development pipeline are bringing forth exciting challenges in drug delivery.
March 02, 2020
Assays can provide a useful tool in determining the potential toxicity of drugs throughout the development cycle.